Alternate Service Delivery Models in Cancer Genetic Counseling: A Mini-Review by Adam Hudson Buchanan et al.
May 2016 | Volume 6 | Article 1201
Mini Review
published: 13 May 2016
doi: 10.3389/fonc.2016.00120
Frontiers in Oncology | www.frontiersin.org
Edited by: 
Sarah M. Temkin, 
National Cancer Institute, USA
Reviewed by: 
Woohyun Yoo, 
Dongguk University, 
South Korea 
Brigitte Mlineritsch, 
Universitätsklinikum Salzburg, Austria 
Takayuki Ueno, 
Kyorin University, Japan
*Correspondence:
Adam Hudson Buchanan  
ahbuchanan@geisinger.edu
Specialty section: 
This article was submitted 
to Women's Cancer, 
a section of the journal 
Frontiers in Oncology
Received: 12 January 2016
Accepted: 28 April 2016
Published: 13 May 2016
Citation: 
Buchanan AH, Rahm AK and 
Williams JL (2016) Alternate Service 
Delivery Models in Cancer Genetic 
Counseling: A Mini-Review. 
Front. Oncol. 6:120. 
doi: 10.3389/fonc.2016.00120
Alternate Service Delivery Models
in Cancer Genetic Counseling: 
A Mini-Review
 
Adam Hudson Buchanan*, Alanna Kulchak Rahm and Janet L. Williams
Geisinger Health System, Genomic Medicine Institute, Danville, PA, USA
Demand for cancer genetic counseling has grown rapidly in recent years as germline 
genomic information has become increasingly incorporated into cancer care, and the 
field has entered the public consciousness through high-profile celebrity publications. 
Increased demand and existing variability in the availability of trained cancer genetics 
clinicians place a priority on developing and evaluating alternate service delivery models 
for genetic counseling. This mini-review summarizes the state of science regarding 
service delivery models, such as telephone counseling, telegenetics, and group coun-
seling. Research on comparative effectiveness of these models in traditional individual, 
in-person genetic counseling has been promising for improving access to care in a 
manner acceptable to patients. Yet, it has not fully evaluated the short- and long-term 
patient- and system-level outcomes that will help answer the question of whether these 
models achieve the same beneficial psychosocial and behavioral outcomes as traditional 
cancer genetic counseling. We propose a research agenda focused on comparative 
effectiveness of available service delivery models and how to match models to patients 
and practice settings. Only through this rigorous research can clinicians and systems 
find the optimal balance of clinical quality, ready and secure access to care, and financial 
sustainability. Such research will be integral to achieving the promise of genomic medi-
cine in oncology.
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inTRODUCTiOn
The world of cancer genetics has experienced exponential growth in diagnostic and treatment oppor-
tunities that use genomic sequencing information, as was most recently acknowledged by the national 
Precision Medicine Initiative (1). Even before the Precision Medicine Initiative, however, demand for 
cancer genetic counseling grew as germline genetic testing became increasingly incorporated into 
breast and ovarian cancer treatment decisions (2, 3), public coverage of celebrity BRCA mutation 
status (4) reached a wide segment of the U.S. population (5), and multi-gene panels for hereditary 
cancer susceptibility were introduced (6, 7). Due to these factors, cancer genetics clinicians across 
the U.S. noted an increase in referrals for hereditary cancer risk assessment (8).
Cancer genetic counseling has traditionally been practiced in person, with patients traveling 
to a health-care facility to meet with a genetics clinician (9). The counseling process has typically 
involved at least two in-person visits – an initial visit to perform risk assessment and, if appli-
cable, informed consent for genetic testing (“pretest counseling”) and for those who underwent 
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genetic testing, a posttest visit to disclose test results and discuss 
results’  implications for cancer risk management in patient and 
family (10).
Pre- and posttest cancer genetic counseling is recognized to 
benefit individuals with cancer and their relatives. Counseling by 
clinicians trained in genetics has been associated with improved 
adherence to cancer risk management (11–14), better informed 
surgical decision making (2, 15), increased cancer genetics 
knowledge (16–19), high patient satisfaction (17, 20), and cost 
savings (21, 22). And, individuals who have undergone cancer 
genetic counseling, even those found to have a hereditary cancer 
syndrome, typically do not report long-term increased distress 
(18,  19, 23–30). Further, negative outcomes such as misinter-
pretation of test results, inappropriate medical management, 
and adverse psychosocial outcomes have been reported when 
genetic testing is performed without adequate genetic counseling 
(13,  21,  22, 31–34). In recognition of these benefits, pre- and 
posttest genetic counseling by qualified health professionals 
is recommended as standard-of-care by several professional 
organizations (35–39).
Yet, the confluence of new genomic sequencing techniques 
and greater public acceptance of cancer genetic counseling 
render the traditional in-person, multi-visit approach to genetic 
counseling insufficient to meet the demands of cancer genetics 
practice in the age of genomic medicine. Further, access to cancer 
genetics professionals varies widely across the U.S. (40–44). Rapid 
access to cancer genetic counselors is readily available in certain 
urban academic centers (45), but several groups, including rural 
residents, are underserved (9, 43, 44).
Alternate service delivery models for cancer genetic services 
have been proposed to improve access to care for individuals in 
underserved areas who are unable to travel to genetic counseling. 
The majority of genetic counselors report having used at least 
one alternate service delivery model (46). Here, we summarize 
the state of the science on alternate service delivery models for 
cancer genetic counseling and recommend future research on the 
effectiveness of these models. First, we present models in which 
genetics clinicians use alternate communication technologies to 
reach patients, followed by alternate visit models (group coun-
seling and non-genetics clinician counseling) and direct-access 
testing models.
ALTeRnATe TeCHnOLOGY MODeLS
Pretest Telephone Counseling
Telephone counseling refers to pretest genetic counseling that is 
provided remotely by telephone (47). It has been used by a sub-
stantial minority of cancer genetic counselors (9). Randomized 
trials comparing telephone with in-person cancer genetic coun-
seling have shown that telephone counseling achieves short-term 
outcomes as well as in-person counseling. These trials have 
shown no difference by group on patients’ knowledge (48, 49), 
psychosocial outcomes (e.g., distress, decisional conflict, and 
cancer worry) (48–50), satisfaction (50, 51), or patient-centered 
communication (49, 50). One study has shown cost savings to 
patients and institutions in telephone vs. in-person cancer genetic 
counseling (48). Among the outstanding research questions in 
telephone genetic counseling is whether telephone counseling 
facilitates psychosocial assessment and counseling to the same 
degree as in-person counseling, a concern raised in two studies 
(51, 52).
Pretest Telephone Counseling and 
educational Materials, Posttest in-Person 
Counseling
A Dutch group has tested a model, termed “DNA-Direct,” that 
uses a telephone consult plus mailed educational information 
for pretest counseling for hereditary breast and ovarian cancer 
syndrome, followed by in-person disclosure of genetic test results 
(53). In a non-randomized comparison of this model with tradi-
tional in-person pre- and posttest genetic counseling, the authors 
found favorable psychosocial outcomes in the DNA-Direct 
model, including lower distress and decisional conflict than in 
the traditional genetic counseling group (53, 54). Time to results 
disclosure was also lower in the DNA-Direct group.
Posttest Telephone Counseling
By far, the most commonly used alternate service delivery model 
in the U.S. is telephone disclosure of genetic test results (i.e., a 
posttest phone visit), which typically follows an in-person pretest 
visit (46). Although disclosure of test results via phone is widely 
used by cancer genetic counselors, a minority of cancer genetic 
counselors report using the phone as the primary model for 
results disclosure (46, 55, 56). Genetic counselors who disclose 
results by phone appreciate the convenience it provides to patients 
(56) and the medical benefits of disclosing results to patients 
more quickly than in-person disclosure, facilitating more timely 
cancer risk management (55, 56). Still, some genetic counselors 
have reported being uncomfortable returning certain genetic test 
results by phone (e.g., mutation positive results) (56).
Telephone disclosure of genetic testing results has been shown 
to be acceptable to patients. A randomized comparison of phone 
vs. in-person disclosure of results showed no difference by 
group in anxiety, distress, cancer genetics knowledge, or patient 
satisfaction (57). Further, this study found that a significantly 
higher proportion of participants in the in-person group would 
have preferred phone disclosure, compared with the proportion 
of phone disclosure participants who would have preferred in-
person disclosure (57). Retrospective, non-randomized studies 
of method of results disclosure have found no difference by 
group (phone vs. in-person) on patient outcomes such as cancer 
worry, cancer risk perception, patient satisfaction, or cancer risk 
management behaviors (e.g., surveillance, prophylactic surgery) 
(55, 58). Of note, patient satisfaction with the model of results 
disclosure was significantly higher when patients were allowed to 
choose the model (55).
Telegenetics
Telegenetics is genetic counseling provided remotely by live 
videoconferencing, with visual and audio access (47). It has been 
most studied in the context of pretest cancer genetic counseling, 
but has been used for posttest counseling, too. Typically, the 
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approach consists of a genetics clinician at an urban health-care 
facility seeing a patient who has come to a different, often rural, 
healthcare facility. It has been used by a substantial minority of 
cancer genetic counselors (9, 46, 59), but is rarely the sole service 
delivery model used by a counselor (9). Patients have reported 
high satisfaction with telegenetics (60–65) due to convenience 
(63) and savings in cost and time (62).
However, comparative effectiveness research on telegenetics is 
limited. Our randomized trial of telegenetics vs. in-person cancer 
genetic counseling found that telegenetics is substantially cheaper 
for institutions than in-person counseling, with no difference in 
patient satisfaction by group (65). But, while early reports show 
that telegenetics may facilitate psychosocial assessment and 
counseling (64), neither behavioral outcomes (e.g., adherence to 
recommended cancer risk management) nor psychosocial out-
comes of cancer telegenetics have been assessed in randomized 
trials (60). Further, data are mixed on whether telegenetics 
actually improves access to care (60). Cohen et  al. found that 
telegenetics was used most for patients who lived more than 2 h 
away from the genetics center, but did not find that telegenetics 
was associated with shorter wait times to an appointment than 
in-person counseling (9). Finally, attendance of cancer genetic 
counseling was lower in the telegenetics than in-person group 
in our randomized trial, indicating that telegenetics may not be 
acceptable to all patients (65).
ALTeRnATe viSiT MODeLS
Group Counseling
Group counseling occurs when multiple individuals have pretest 
genetic counseling together, typically for the same indication (e.g., 
all have a family history of breast cancer) (47). Group counseling 
can be performed via multiple communication technologies, 
though it is typically performed in person. Depending on the 
study, patients may have the opportunity for individual discus-
sions of personal issues with a genetics clinician immediately 
after the group session (16, 66) or via a subsequent telephone 
consult (67). Group genetic counseling has been used by up to 
10% of cancer genetic counselors, but is rarely the sole service 
delivery model used by a counselor (9, 46).
Group genetic counseling has shown promise for increasing 
efficiency by decreasing per-patient time for genetics clinicians 
(16, 67). And, a randomized comparison of group vs. individual 
cancer genetic counseling showed no difference by group in can-
cer-specific distress or knowledge of breast cancer genetics (16). 
Similarly, a non-randomized comparison of group vs. individual 
cancer genetic counseling showed no difference in perceived 
personal control, cancer-specific distress, or patient satisfaction 
(66). However, questions remain about whether group counseling 
would be widely accepted by cancer genetic counseling patients. 
One study showed a high rate of declining group counseling, con-
cerns about the effects of group dynamics on patients’ privacy and 
decision making, and a preference for individual counseling over 
group counseling (67). A later, non-randomized study echoed this 
preference for individual counseling when patients were given 
the choice of service delivery model (66). This study also showed 
a lower rate of genetic testing uptake in the group  counseling 
cohort than in the individual counseling cohort, though it is 
unclear whether this was due to a difference by cohort in the 
proportion of individuals for whom genetic testing was indicated 
or to a difference by cohort in the informed consent process (66). 
Further, it is not clear whether group genetic counseling improves 
access to care in underserved areas (9). And, as with other service 
delivery models, reimbursement for group counseling remains a 
challenge (9).
non-Genetics Clinician Counseling
Several additional models in which a non-genetics clinician is 
the primary provider of genetic counseling have been described. 
These include models in which non-genetics clinicians provide 
pretest counseling and refer either all patients to a genetics 
clinician posttest or just patients considered complex; genetic 
counselors assist non-genetics clinicians in risk assessment and 
pre- and posttest counseling, and may see some complex cases 
themselves; and a genetic counselor educates a community of cli-
nicians on pre- and posttest counseling and trains them to man-
age routine cases and refer complex cases (46). Although these 
models appear to be fairly widely used, with up to 36% of genetic 
counselors having been involved in one of these models (46), data 
on the comparative effectiveness of these models for improving 
access to care or facilitating the same beneficial behavioral and 
psychosocial outcomes as two-visit, in-person genetic counseling 
by trained genetics clinicians is lacking.
DiReCT-ACCeSS GeneTiC TeSTinG
Also known as direct-to-consumer testing, direct-access testing 
occurs when individuals order their own genetic testing from a 
commercial laboratory outside the context of a typical medical 
encounter and receive results and associated educational materi-
als directly. Although much of the available direct-access testing 
focuses on genomic variants with a modest impact on cancer 
risk, some tests do report mutations in genes associated with 
hereditary cancer syndromes (e.g., BRCA1/2). It is also possible 
for patients to initiate testing for hereditary cancer syndromes 
through companies that coordinate with their physicians and 
provide access to genetic counseling. Data on patient outcomes of 
direct-access testing for hereditary cancer syndromes are limited, 
with case reports showing both benefits of this approach as a way 
to be tested without concern for genetic discrimination (68) and 
concerns about increased psychological stress when a BRCA 
mutation is detected incidentally via direct-access testing (69). 
Preliminary qualitative research suggests that initial negative psy-
chological outcomes of direct-access identification of hereditary 
cancer risk may be temporary (70). As direct-access models grow 
in prevalence, comparative effectiveness studies with traditional 
genetic counseling models will become necessary.
DiSCUSSiOn
Alternate service delivery models have the potential for improv-
ing access to cancer genetic counseling, which is of growing 
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importance as germline genomic information is increasingly 
incorporated into the care of individuals with cancer and their at-
risk relatives. Such improved access may mitigate health dispari-
ties and help achieve the significant promise of genomic medicine 
(71). Telephone counseling, group counseling, and telegenetics 
have been well accepted by patients and may facilitate the patient-
centered communication and psychosocial assessment that are 
the hallmark of cancer genetic counseling (16, 48, 51, 64, 65). 
Yet, considerable comparative effectiveness research is necessary 
to determine whether alternate service delivery models are as 
beneficial as in-person cancer genetic counseling. This holds true 
for alternate service delivery models provided by genetics and 
non-genetics clinicians. The latter is particularly important, given 
reports of negative outcomes of non-genetics clinicians providing 
cancer genetic counseling (13, 21, 22, 32–34).
Further studies are needed on the degree to which alternate 
service delivery models improve access to cancer genetic coun-
seling. And here, we mean access broadly defined, not simply a 
patient’s ability to be seen with limited disruption of their daily 
responsibilities, though this is important. Ideally, access would 
mean that patients can have cancer genetic counseling that is read-
ily available, affordable, and comparable to in-person counseling 
on outcomes of import to patients, genetics clinicians, and refer-
ring clinicians. Determining whether an alternate service model 
(or suite of models) is comparable to in-person counseling will 
require rigorous methodology and a focus on  patient-centered 
outcomes such as longer-term psychosocial outcomes and 
adherence to recommended cancer risk management (60, 65). 
Studies conducted with a cost analysis that includes real-world 
reimbursement of genetic counseling  –  a significant challenge 
to broad implementation of all alternate service delivery models 
(9, 72, 73) – will also be critical.
One additional lesson of comparisons of alternate service 
delivery models with traditional in-person cancer genetic 
counseling is that one size will not fit all. Uptake of cancer 
genetic counseling has differed by service delivery model (48, 
53, 65–67), and patients may be most satisfied when they are 
allowed to choose the method in which they have genetic 
counseling (55). This suggests a pragmatic research agenda that 
helps match service delivery models to patients and practice 
settings. Such research should investigate the wide variety of 
patient characteristics that could impact their preference for a 
particular service delivery model [e.g., cancer status (affected vs. 
unaffected), demographic characteristics, comfort with technol-
ogy, and distance to the nearest genetics facility]. Clinically, the 
lesson that one size will not fit all suggests that cancer genetic 
counseling patients will be best served by being presented with 
a variety of service delivery models and allowed to choose their 
preferred model.
Using alternate service delivery models to provide cancer 
genetic counseling involves balancing several factors thought to 
be important to the clinical experience, including patients’ access 
to care and clinicians’ perceptions of their own effectiveness to 
clearly explain potentially complex genetics concepts while 
assessing and responding to psychosocial cues. And, models 
ultimately need to strike this balance while maintaining patients’ 
confidentiality, fitting into healthcare systems’ work flows, 
and being financially viable. Telegenetics, which facilitates an 
educational and empathetic interaction quite similar to an in-
person conversation (63), holds promise for meeting the clinical 
rigor genetics clinicians expect. And, several videoconferencing 
programs have the necessary security protocols to maintain 
confidentiality. But, studies of telegenetics to date have focused 
on a model in which patients must attend a local health-care 
facility, potentially limiting some patients’ access and requiring 
staff at the remote clinic to facilitate patients’ interaction with the 
genetics clinician. With U.S. Internet use approaching 90% (74) 
and the proliferation of smartphones (75), telegenetics sessions 
that meet patients where they are on their preferred device may 
provide an even better balance of rapid access and high-quality 
care that has a minimal impact on clinics’ work flows. Whether 
such a model would be financially viable or help genetics clini-
cians meet growing demand for their services, however, remains 
to be seen.
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